-

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 9, 2026 to June 24, 2026

DEADLINE: October 5, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew or recklessly disregarded the risk of timeline problems related to CVS Caremark’s addition of neffy to its formulary. The Company’s guidance on the timeline for insurance coverage for neffy may shift considerably, impacting its commercialization. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about ARS, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses.

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

Schall, Brown & Schwartz LLP

NASDAQ:SPRY

Release Summary
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Release Versions
$Cashtags

Contacts

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

More News From Schall, Brown & Schwartz LLP

AGCO Investors Have Opportunity to Join AGCO Corporation Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)--AGCO Investors Have Opportunity to Join AGCO Corporation Fraud Investigation with SBS Law...

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law...

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES--(BUSINESS WIRE)--REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law...
Back to Newsroom